Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Jul 23, 2026 · most recent call
WST’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: West Pharmaceutical Services’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: WST daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $749M | +2.2% | $1.78 | -2.7% | 36.7% | 22.8% | 17.4% | $85M |
| FY2025 Q1 | $698M | +0.4% | $1.23 | -20.6% | 33.3% | 18.4% | 12.9% | $58M |
| FY2025 Q2 | $766M | +9.1% | $1.82 | +20.5% | 35.7% | 20.6% | 17.2% | $102M |
| FY2025 Q3 | $804M | +7.7% | $1.93 | +4.3% | 36.5% | 21.6% | 17.4% | $134M |
| FY2025 Q4 | $805M | +7.5% | $1.82 | +2.2% | 37.8% | 19.5% | 16.4% | $175M |
| FY2026 Q1 | $845M | +21.0% | $1.92 | +56.1% | 35.1% | 21.0% | 16.4% | $47M |
| FY2026 Q2Selected | $872M | +13.8% | $2.15 | +18.1% | 37.7% | 20.5% | 17.7% | $81M |
Management-stated figures from WST’s newest call are part of Tellvest Pro.
No 8-K events recorded since this call day.